MX2024007070A - Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. - Google Patents

Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.

Info

Publication number
MX2024007070A
MX2024007070A MX2024007070A MX2024007070A MX2024007070A MX 2024007070 A MX2024007070 A MX 2024007070A MX 2024007070 A MX2024007070 A MX 2024007070A MX 2024007070 A MX2024007070 A MX 2024007070A MX 2024007070 A MX2024007070 A MX 2024007070A
Authority
MX
Mexico
Prior art keywords
alz
disease
treating alzheimer
alzheimer
treating
Prior art date
Application number
MX2024007070A
Other languages
English (en)
Spanish (es)
Inventor
Susan Abushakra
Martin Tolar
John Hey
Neil William Flanzraich
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzheon Inc filed Critical Alzheon Inc
Publication of MX2024007070A publication Critical patent/MX2024007070A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2024007070A 2021-12-09 2022-12-09 Alz-801 para uso en el tratamiento de la enfermedad de alzheimer. MX2024007070A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163287552P 2021-12-09 2021-12-09
PCT/US2022/052331 WO2023107658A1 (en) 2021-12-09 2022-12-09 Alz-801 for use in treating alzheimer's disease

Publications (1)

Publication Number Publication Date
MX2024007070A true MX2024007070A (es) 2024-08-22

Family

ID=85157530

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007070A MX2024007070A (es) 2021-12-09 2022-12-09 Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.

Country Status (10)

Country Link
US (1) US20250041248A1 (enExample)
EP (1) EP4444286A1 (enExample)
JP (1) JP2024542844A (enExample)
KR (1) KR20240116529A (enExample)
CN (1) CN118678950A (enExample)
AU (1) AU2022405026A1 (enExample)
CA (1) CA3240392A1 (enExample)
IL (1) IL313404A (enExample)
MX (1) MX2024007070A (enExample)
WO (1) WO2023107658A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3347002T (pt) * 2015-09-10 2023-07-27 Alzheon Inc Tratamento de doença de alzheimer numa população particular de pacientes
DK3829563T3 (en) * 2018-08-01 2025-02-24 Alzheon Inc 3-sulfopropanoic acid for treating neurodegenerative disorders

Also Published As

Publication number Publication date
AU2022405026A1 (en) 2024-06-20
JP2024542844A (ja) 2024-11-15
EP4444286A1 (en) 2024-10-16
IL313404A (en) 2024-08-01
CA3240392A1 (en) 2023-06-15
WO2023107658A1 (en) 2023-06-15
US20250041248A1 (en) 2025-02-06
KR20240116529A (ko) 2024-07-29
CN118678950A (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
CL2021001575A1 (es) Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora específica de ubiquitina 1 (usp1)
BR112022016382A2 (pt) Triptaminas específicas para o uso no tratamento de doenças do humor
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
EA202092154A1 (ru) Комбинированная терапия
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
MX378579B (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
CR20190361A (es) Dendrímeros terapéuticos
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2022010693A (es) Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades.
CL2024000867A1 (es) Compuestos de imidazopiridazina inhibidores de il-17.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
CO2022010592A2 (es) Métodos de tratamiento de la esplenomegalia
MX382357B (es) Métodos y composiciones para tratar infecciones fúngicas cutáneas.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
CL2021000269A1 (es) Métodos para tratar trastornos neurodegenerativos
JOP20230173A1 (ar) أشطر إطالة العمر-النصفي وطرق استخدامها
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
BR112019007214A2 (pt) composições do apilimode e métodos para uso do mesmo no tratamento do mal de alzheimer
BR112022025128A2 (pt) Composições e métodos para tratar doenças e distúrbios usando vesículas extracelulares microbianas de oscillospiraceae
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها